Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELOXX PHARMACEUTICALS, INC.

(ELOX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eloxx Pharmaceuticals : to Host Investor and Analyst Call and Webcast on Cystic Fibrosis Programs

10/07/2021 | 04:16pm EST

Globally renowned CF Expert, Dr. Eitan Kerem will provide key insights

Data from ongoing Phase 2 trials in CF expected in 4Q 2021

WATERTOWN, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that it will host an Investor and Analyst call and webcast on Tuesday, October 12, 2021. The event will include an update on the company’s cystic fibrosis programs and will feature Dr. Eitan Kerem, a globally renowned CF expert. The event is intended to provide insight into Eloxx’ CF programs, as data from the ongoing Phase 2 trials in CF are expected in the fourth quarter of 2021.

Date: Tuesday, October 12, 2021
Time: 10:00 a.m. ET
Domestic Dial-in Number: (866) 913-8546
International Dial-in Number: (210) 874-7715
Conference ID: 8378144
Live Webcast and Presentation Materials: accessible from the Company's website at www.eloxxpharma.com under Events and Presentations.

A replay of the webcast and presentation materials will be available on the Company’s website at www.eloxxpharma.com under Events and Presentations for at least 30 days.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is engaged in the science of ribosome modulation, leveraging both its innovative TURBO-ZM™ chemistry technology platform in an effort to develop novel Ribosome Modulating Agents (RMAs) and its library of Eukaryotic Ribosome Selective Glycosides (ERSGs). Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in clinical development focusing on cystic fibrosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx also has preclinical programs focused on select rare diseases including inherited diseases, cancer caused by nonsense mutations, kidney diseases, including autosomal dominant polycystic kidney disease, as well as rare ocular genetic disorders.

For more information, please visit www.eloxxpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present and historical facts contained in this press release, including without limitation, statements regarding the potential of our product candidate to treat nonsense mutations are forward-looking statements. Forward-looking statements can be identified by the words “aim,” “may,” “will,” “would,” “should,” “expect,” “explore,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “seeks,” or “continue” or the negative of these terms similar expressions, although not all forward-looking statements contain these words.

Forward-looking statements are based on management's current plans, estimates, assumptions and projections based on information currently available to us. Forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and actual results or outcomes may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: our ability to progress any product candidates in preclinical or clinical trials; the uncertainty of clinical trial results and the fact that positive results from preclinical studies are not always indicative of positive clinical results; the scope, rate and progress of our preclinical studies and clinical trials and other research and development activities; the competition for patient enrollment from drug candidates in development; the impact of the global COVID-19 pandemic on our clinical trials, operations, vendors, suppliers, and employees; our ability to obtain the capital necessary to fund our operations; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain financial in the future through product licensing, public or private equity or debt financing or otherwise; general business conditions, regulatory environment, competition and market for our products; and business ability and judgment of personnel, and the availability of qualified personnel and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, as any such factors may be updated from time to time in our other filings with the SEC, accessible on the SEC’s website at www.sec.gov and the “Financials & Filings” page of our website at https://investors.eloxxpharma.com/financial-information/sec-filings.

All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact

Investors
John Woolford
john.woolford@westwicke.com
443.213.0506

Media
Laureen Cassidy
laureen@outcomescg.com

SOURCE: Eloxx Pharmaceuticals, Inc.


All news about ELOXX PHARMACEUTICALS, INC.
11/18HC Wainwright Adjusts Eloxx Pharmaceuticals' Price Target to $1 From $2, Keeps Neutral ..
MT
11/17ELOXX PHARMACEUTICALS : Topline ELX-02 Phase 2 Results Call and Webcast
PU
11/17Eloxx Pharmaceuticals' Mid-Stage Cystic Fibrosis Trial Meets Key Secondary Endpoint, Sa..
MT
11/17ELOXX PHARMACEUTICALS : Reports Positive Topline Results from Monotherapy Arms of Phase 2 ..
PU
11/17ELOXX PHARMACEUTICALS, INC. : Regulation FD Disclosure, Other Events, Financial Statements..
AQ
11/17Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2..
AQ
11/17Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2..
CI
11/11HC Wainwright Adjusts Eloxx Pharmaceuticals' Price Target to $2 From $3, Maintains Neut..
MT
11/09Eloxx Pharmaceuticals Reports Third Quarter 2021 Financial and Operating Results and Pr..
PU
11/09Eloxx Pharmaceuticals, Inc. Appoints Ali Hariri as Chief Medical Officer
CI
More news
Analyst Recommendations on ELOXX PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -64,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,76x
Yield 2021 -
Capitalization 62,7 M 62,7 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 25
Free-Float 90,3%
Chart ELOXX PHARMACEUTICALS, INC.
Duration : Period :
Eloxx Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELOXX PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 0,73 $
Average target price 3,33 $
Spread / Average Target 359%
EPS Revisions
Managers and Directors
Sumit Aggarwal President, Chief Executive Officer & Director
Daniel E. Geffken Chief Financial & Accounting Officer
Tomer Kariv Chairman
Vijay Modur Head-Research & Development
Ali Hariri Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ELOXX PHARMACEUTICALS, INC.-81.74%63
MODERNA, INC.188.59%122 239
LONZA GROUP AG25.98%57 878
IQVIA HOLDINGS INC.46.64%50 192
SEAGEN INC.-9.40%29 014
CELLTRION, INC.-41.36%24 745